Darzalex Add-on Delays Disease Progression or Death in Newly Diagnosed Multiple Myeloma, Phase 3 Trial Shows
Treatment with Darzalex (daratumumab) plus standard Revlimid (…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Myeloma Crowd Launches Online Tool to Help Patients Find Treatment Options, Contribute to Research
Myeloma Crowd has launched an online tool called…
New Compound Safely Halts Advanced Myeloma Progression in Small Pilot Study
A new investigational compound targeting a central…
Trip to Mount Everest’s Base Benefits MMRF-funded Multiple Myeloma Research
During a strenuous but spectacular hike, a team including…
Revlimid Delays Disease Progression in Smoldering Myeloma Patients, Preliminary Trial Results Show
Celgene‘s immunomodulatory agent Revlimid (lenalidomide) significantly extended the time…
Darzalex Add-on Increases Complete Responses After Stem Cell Transplant, Phase 3 Myeloma Trial Shows
Adding Darzalex (daratumumab) to the standard pre-transplant therapy…
